


=> d 12; d his; log y

L2 HAS NO ANSWERS

L1 STR



G2

G1 O,S,N

G2 [@1], [@2], [@3], [@4], [@5], [@6]

Structure attributes must be viewed using STN Express query preparation.

L2 QUE ABB=ON PLU=ON L1

(FILE 'HOME' ENTERED AT 16:43:14 ON 09 MAR 2006)

FILE 'REGISTRY' ENTERED AT 16:43:27 ON 09 MAR 2006

L1 STRUCTURE uploaded  
L2 QUE L1  
L3 0 S L2  
L4 3 S L2 FUL

FILE 'CAPLUS' ENTERED AT 16:44:12 ON 09 MAR 2006


L5 1 S L4

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	5.57	172.72
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.75	-0.75

STN INTERNATIONAL LOGOFF AT 16:45:04 ON 09 MAR 2006

LS ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2001:115130 CAPLUS Full-text  
 DN 134:178474  
 TI Preparation of oxobenzazepinealkanoates and analogs as integrin receptor antagonists  
 IN Kling, Andreas; Geneste, Herve; Lange, Udo; Lauterbach, Arnulf; Graef, Claudia Isabella; Subkowski, Thomas; Holzenkamp, Uta; Mack, Helmut; Sadowski, Jens; Hornberger, Wilfried; Laux, Volker  
 PA BASF Aktiengesellschaft, Germany  
 SO PCT Int. Appl., 158 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA German  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001010847	A2	20010215	WO 2000-EP7440	20000801
	WO 2001010847	A3	20011101		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	DE 19936780	A1	20010215	DE 1999-19936780	19990809
	CA 2379977	AA	20010215	CA 2000-2379977	20000801
	EP 1202988	A2	20020508	EP 2000-958347	20000801
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	BR 2000013265	A	20020514	BR 2000-13265	20000801
	TR 200200357	T2	20020923	TR 2002-200200357	20000801
	JP 2003506441	T2	20030218	JP 2001-515313	20000801
	BG 106395	A	20021229	BG 2002-106395	20020206
	NO 2002000644	A	20020318	NO 2002-644	20020208
PRAI	DE 1999-19936780	A	19990809		
	WO 2000-EP7440	W	20000801		
OS	MARPAT	134:178474			
GI					



AB RZZ1R1 [I; R = group contg,  $\geq 1$  non-H H-bonding atom; R1 = CO2H, or group hydrolizable to CO2H; Z = e.g., (hetero)annulated 2-oxo-1-benzazepin-1,5-diyl; Z1 = bond, (un)substituted NHCH2, -OCH2, -alkylene, -CH:CH, etc.] were prepared. Thus, Me 11-methoxycarbonylmethyl-6-oxo-6,11-dihydro-5H-dibenz[b,e]azepine-5-acetate (preparation given) was amidated by N-(2-aminoethyl)pyridine-2-amine to give, after saponification, title compound II. Data for biol. activity of I were given.


IT 326402-02-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of oxobenzazepinealkanoates and analogs as integrin receptor antagonists)

RN 326402-02-2 CAPLUS

CN 5H-Dibenz[b,e]azepine-5-acetic acid, 11-[2-[[[4-(1H-benzimidazol-2-ylamino)phenyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, monohydrochloride (9CI) (CA INDEX NAME)



IT 326408-68-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation of oxobenzazepinealkanoates and analogs as integrin receptor antagonist)

RN 326408-68-8 CAPLUS

CN 5H-Dibenz[b,e]azepine-5-acetic acid, 11-[2-[[[4-(1H-benzimidazol-2-ylamino)phenyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

